Immuneering Corporation Increase (Decrease) in Accounts Receivable
Immuneering Corporation (IMRX) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-20.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-03-20
- Immuneering Corporation increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was $0.00.
- Immuneering Corporation increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $0.00.
- Immuneering Corporation increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was $0.00.
- Immuneering Corporation increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $0.00.
- Immuneering Corporation increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- Immuneering Corporation increase (decrease) in accounts receivable for fiscal 2023 was -$12.42K.
- Immuneering Corporation increase (decrease) in accounts receivable for fiscal 2022 was -$233.62K.
- Immuneering Corporation increase (decrease) in accounts receivable for fiscal 2021 was -$279.71K, a 196.40% decline from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | $0.00 derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | $0.00 derived: sum of 3 quarters · filed 2025-03-20 | -$1.05K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | -$1.05K derived: sum of 3 quarters · filed 2025-03-20 | -$12.42K 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.05K derived: sum of 2 quarters · filed 2024-11-13 | -$12.42K 10-Q · filed 2024-11-13 | -$70.18K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$1.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$12.42K 10-Q · filed 2024-08-06 | -$70.18K derived: sum of 3 quarters · filed 2024-08-06 | -$178.43K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$11.37K 10-Q · filed 2024-05-07 | -$69.13K derived: sum of 2 quarters · filed 2024-05-07 | -$177.38K derived: sum of 3 quarters · filed 2024-05-07 | -$278.57K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$57.76K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$166.01K derived: sum of 2 quarters · filed 2024-03-01 | -$267.20K derived: sum of 3 quarters · filed 2024-03-01 | -$233.62K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$108.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$209.43K derived: sum of 2 quarters · filed 2023-11-09 | -$175.86K 10-Q · filed 2023-11-09 | -$426.84K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$101.19K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$67.61K 10-Q · filed 2023-08-03 | -$318.59K derived: sum of 3 quarters · filed 2023-08-03 | -$342.32K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $33.57K 10-Q · filed 2023-05-04 | -$217.41K derived: sum of 2 quarters · filed 2023-05-04 | -$241.13K derived: sum of 3 quarters · filed 2023-05-04 | -$238.44K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$250.98K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$274.71K derived: sum of 2 quarters · filed 2023-03-06 | -$272.01K derived: sum of 3 quarters · filed 2023-03-06 | -$279.71K 10-K · filed 2023-03-06 |
| 2021-09-30 | -$23.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$21.03K derived: sum of 2 quarters · filed 2022-11-10 | -$28.73K 10-Q · filed 2022-11-10 | -$106.77K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$5.00K 10-Q · filed 2022-08-10 | -$83.04K derived: sum of 3 quarters · filed 2022-08-10 | $195.15K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$7.71K 10-Q · filed 2022-05-10 | -$85.74K derived: sum of 2 quarters · filed 2022-05-10 | $192.44K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$78.03K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $200.15K derived: sum of 2 quarters · filed 2022-03-10 | $290.17K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $278.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $368.20K 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $90.02K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |